Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nabilone controlled release - AOP Orphan Pharmaceuticals

Next Previous
Drug Profile

Nabilone controlled release - AOP Orphan Pharmaceuticals

Alternative Names: Nabilone FDT

Latest Information Update: 30 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AOP Orphan Pharmaceuticals AG
  • Developer AOP Orphan Pharmaceuticals AG; Innsbruck Medical University
  • Class Antiemetics; Cannabinoids; Non-opioid analgesics; Small molecules
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Parkinson's disease
  • Phase II Pain

Most Recent Events

  • 04 Mar 2021 Nabilone controlled release is still in phase III trials for Parkinson's disease (Treatment-experienced) in Austria (PO) (EudraCT2017-004253-16)
  • 20 Feb 2020 Orthopädisches Spital Speising GmbH and AOP Orphan Pharmaceuticals completes the phase II Cannabinoid-Spinal-Fusion-Study trial for Pain in Austria (PO, Capsule) (EudraCT2015-004227-31)
  • 15 Jul 2019 AOP Orphan Pharmaceuticals completes a phase II trial in Parkinson's disease in Austria (EudraCT2017-000192-86)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top